Publication
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors.
Authors not recorded
Clin Cancer Res2021PMID 34074656PMC8900067stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerBladder Urothelial Carcinomacivic_curation1.00
- drugImmune Checkpoint Inhibitorcivic_curation1.00
- geneCDKN2Acivic_curation1.00
- variantCDKN2A Losscivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 34074656
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CDKN2A Loss1 | ||||||||
| Immune Checkpoint Inhibitor | Bladder Urothelial Carcinoma | Predictive | B | Supports Resistance | 3 | accepted | EID12546In retrospective analyses of two large ICI-treated solid tumor cohorts (DFCI n = 789, MSKCC n = 1250), CDKN2A loss-of-function alterations were associated with significantly worse overall survival and… (full text at CIViC) PMID 34074656 · Adib et al., 2021 · Open in CIViC | civic |